Literature DB >> 7903402

Characterization of non-opioid [3H]dynorphin A-(1-13) binding sites in the rat heart.

M Dumont1, S Lemaire.   

Abstract

The binding characteristics of [3H]Dynorphin A-(1-13) ([3H]Dyn A-(1-13) were examined in membrane preparations of rat heart. Saturation binding studies with increasing concentrations between 2.5 and 500 nM indicated that [3H]Dyn A-(1-13) binds to a single population of sites with a Kd of 285 nM and a Bmax of 215 pmol/mg protein. [3H]Dyn A-(1-13) binding is sensitive to trypsin treatment and it is inhibited by Zn2+ and Mg2+ with IC50 values of 159 and 310 microM, respectively. Dyn A and related peptides competes with the binding of [3H]Dyn A-(1-13) with the following order of potency: Dyn A-(1-13) > Dyn A > Dyn B > alpha-neo-endorphin > Dyn A-(1-8). The non-opioid peptides Dyn A-(2-13), Dyn A-(3-13) and Dyn A-(5-13) are as potent (Ki of 0.35, 0.44 and 0.59 microM, respectively) as Dyn A-(1-13) (Ki of 0.36 microM) in inhibiting [3H]Dyn A-(1-13) binding while Leu-enkephalin (Leu-Enk) exhibits no inhibitory effect at 100 microM. Selective ligands for kappa (kappa: U-50,488H, U-69,593), mu (mu: [D-Ala2, MePhe4, Glyol5]Enk) and delta (delta: [D-Ser2, Thr6]Leu-Enk) opioid receptors as well as for phencyclidine (PCP: MK-801, TCP) and sigma (sigma: (+)-SKF-10047, DTG, 3(+)-PPP) receptors show little or no inhibition of [3H]Dyn A-(1-13) binding at 100 microM. These results indicate that the heart contains a low affinity high capacity binding site for Dyn A and related peptides, distinct from opioid, PCP and sigma receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903402     DOI: 10.1006/jmcc.1993.1110

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  3 in total

1.  Dynorphin peptides: antagonists of melanocortin receptors.

Authors:  J M Quillan; W Sadée
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

2.  A direct chemical interaction between dynorphin and excitatory amino acids.

Authors:  A Woods; A Zangen
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

Review 3.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.